Geron's Rytelo Ramp Faces A Math Test As Stock Slides Toward Its Lows

Geron enters its third-quarter report with an awkward disconnect. Management closed its last call sounding more confident than at any point since the reset of late 2025, nudging its Rytelo revenue outlook toward the upper half of the range. Yet the stock has fallen about 16% since then, trailing a roughly flat S&P 500 by nearly 15 percentage points. Either the market doubts the ramp can keep pace with that upgraded tone, or it is overlooking a business that is quietly improving. The November 4 release, due before the open, should help settle which view is closer to the truth.

The Street is looking for revenue of about $60 million, up 27% from the soft $47.2 million posted a year ago, and a loss of roughly a penny per share versus three cents in the year-ago quarter. The year-over-year comparison flatters the quarter, since last year's third quarter was the trough when demand actually slipped sequentially. The more revealing figure is sequential growth: $60 million would be only about 4% above the second quarter's $57.5 million, a noticeable slowdown from the 11% jump last time.

That matters because of the guidance arithmetic. Geron took in about $109 million in the first half. Hitting the midpoint of its $220 million to $240 million range requires roughly $60 million per quarter in the back half, while the high end implies something closer to $65 million. Consensus therefore sits right at the floor of what management's mid-to-high-end language implies. A print near $60 million would keep the guidance credible but would not prove the upward skew. Something in the low-to-mid $60 millions would validate the confidence; a figure in the high $50 millions would make the upgrade look premature and put pressure on the fourth quarter.

The underlying drivers deserve as much attention as the headline number. Management credited community practices for most of the growth, with prescribing accounts climbing to roughly 1,575, though that pace of additions cooled from 12% to 8% sequentially. Continued account expansion, alongside further gains in the share of patients starting Rytelo in first and second line, now at 34%, would suggest the ramp has depth rather than relying on a pool of early adopters. Gross-to-net deductions, which climbed to about 20.7%, are the quieter risk. Management expects them to hold in the low-to-mid 20s, and any drift above that would chip away at net revenue even if demand holds. On costs, Geron has trimmed operating expenses while revenue grew, and keeping spending inside its $230 million to $240 million plan would keep cash burn slowing from a $327 million balance.

There are strategic threads to tug as well. Management promised to share European commercialization plans before year-end, a decision complicated by most-favored-nation pricing concerns, and the new chief business officer signals interest in deals. Any update on the proposed change to the IMPACT-MF interim analysis threshold would also be relevant, though the base case still points to a final readout in the second half of 2028.

Sentiment has soured, with bearish readings rising from about 35% before last quarter to nearly 50% now, and the stock at $1.15 sits well below its 200-day average of $1.43 and only a few cents above its post-earnings low of $1.08. That backdrop lowers the bar for a positive reaction but leaves little cushion for disappointment. Ultimately, the report hinges on whether sequential growth stays strong enough to make the high half of guidance look achievable. If it does, the gap between fundamentals and the share price becomes hard to ignore; if it does not, the bears' skepticism will look justified.

This earnings preview was originally published on Earnings Whispers.

This article is for informational purposes only and is not investment advice. Earnings Whispers and its staff may hold positions in the securities mentioned. It is AI-assisted, based on proprietary Earnings Whispers data and company reports, and edited by Earnings Whispers staff.